SEC Form SC 13G/A filed by CalAmp Corp. (Amendment)

$CAMP
Get the next $CAMP alert in real time by email
SC 13G/A 1 fp0081851-1_sc13ga.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

 

(AMENDMENT NO. 3)*

 

CALAMP CORP.

(Name of Issuer)

 

Common Stock, Par Value of $0.01 Per Share

(Title of Class of Securities)

 

128126109

(CUSIP Number)

 

Michelle Gosom

Aristotle Capital Boston, LLC

One Federal Street, 36th Floor

Boston, MA 02110

617-274-4300

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

December 31, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[X] Rule 13d-1(b)

[  ] Rule 13d-1(c)

[  ] Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

   

 

CUSIP No. 128126109   13G   Page 2 of 5 Pages

 

1.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Aristotle Capital Boston, LLC

 
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a) [ ]

(b) [ ]

3.

SEC USE ONLY

 

 
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

State of Massachusetts

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5.

SOLE VOTING POWER

 

2,290,619

6.

SHARED VOTING POWER

 

None

7.

SOLE DISPOSITIVE POWER

 

2,650,744

8.

SHARED DISPOSITIVE POWER

 

None

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

2,650,744

 
10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions) [ ]

 

 
11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.17%

 
12.

TYPE OF REPORTING PERSON (see instructions)

 

IA

 

   

 


CUSIP No. 128126109   13G   Page 3 of 5 Pages

 

Item 1. (a)

Name of Issuer

CALAMP CORP.

     
  (b)

Address of Issuer’s Principal Executive Offices

15635 Alton Parkway

Suite 250

Irvine, California 92618

 

Item 2. (a)

Name of Person Filing

Aristotle Capital Boston, LLC

     
  (b)

Address of the Principal Office or, if none, residence

One Federal Street, 36th Floor

Boston, Massachusetts 02110

     
  (c)

Citizenship

State of Massachusetts

     
  (d)

Title of Class of Securities

Common Stock, Par Value of $0.01 Per Share

     
  (e)

CUSIP Number

128126109

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
  (h) [  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).
   

 

CUSIP No. 128126109   13G   Page 4 of 5 Pages

 

Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a) Amount beneficially owned: 2,650,744
(b) Percent of class: 7.17%
(c) Number of shares as to which the person has:  
  (i) Sole power to vote or to direct the vote: 2,290,619
  (ii) Shared power to vote or to direct the vote: None
  (iii) Sole power to dispose or to direct the disposition of: 2,650,744
  (iv) Shared power to dispose or to direct the disposition of: None

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Instruction. Dissolution of a group requires a response to this item.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

All of the shares of Common Stock set forth in Item 4 are owned by various investment advisory clients of Aristotle Capital Boston, LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares for its clients and/or its ability to vote such shares. In all cases, persons other than Aristotle Capital Boston, LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares. No individual client holds more than five percent of the class.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

   

 

CUSIP No. 128126109   13G   Page 5 of 5 Pages

 

Item 10. Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  Aristotle Capital Boston, LLC  
       
  By: /s/ Michelle M. Gosom  
  Name: Michelle M. Gosom  
  Title: Chief Compliance Officer  
       
  Date: February 14, 2023  

   

 

 

Get the next $CAMP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CAMP

DatePrice TargetRatingAnalyst
11/5/2024Outperform
William Blair
11/5/2024$18.00Overweight
Piper Sandler
11/5/2024$23.00Overweight
JP Morgan
8/16/2022$8.00 → $10.00Hold → Buy
Craig Hallum
12/22/2021$15.00 → $14.00Buy
Canaccord Genuity
12/22/2021$14.00 → $10.00Buy → Hold
Craig-Hallum
9/24/2021$16.00 → $14.00Buy
Craig Hallum
6/25/2021$19.00 → $18.50Buy
Roth Capital
More analyst ratings

$CAMP
Press Releases

Fastest customizable press release news feed in the world

See more
  • CAMP4 to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences: Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFormat:   Corporate PresentationDate and Time:  February 12, 2025, 10:00 a.m. ESTLocation:  VirtualWebcast Link:  Click Here    Leerink Partners Global Healthcare ConferenceFormat:  Fireside ChatDate and Time:  March 1

  • CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15, 2025, at 3:45 p.m. PST. The event will be webcast live and can be accessed on the investor relations page of CAMP4's website at www.investors.camp4tx.com. A replay of the webcast will be archived on the C

  • CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

    Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two Multiple Ascending Dose (MAD) cohorts, and initiated dosing in Cohort 3MAD safety and key study biomarker data expected in 2H 2025CAMP4 added to Russell 2000® IndexInitiation of new discovery program targeting a GBA1 regRNA for the treatment of Parkinson's disease (PD)Company to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 at 3:45 p.m. PST CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinic

$CAMP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CAMP
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAMP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAMP
SEC Filings

See more

$CAMP
Leadership Updates

Live Leadership Updates

See more
  • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CalAmp Appoints Chris Adams as President and Chief Executive Officer

    IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

  • CalAmp Announces CEO Transition

    IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced that Jeff Gardner will be stepping down from his role as Chief Executive Officer, effective no later than October 30, 2023. The Company has commenced a search for its next CEO and will be retaining an executive search firm. In announcing his departure, Jeff Gardner shared, "It has been a privilege working with the amazing group of colleagues at CalAmp. I am proud of all that we have accomplished and the progress we have made in positioning the Company for growth and p

$CAMP
Financials

Live finance-specific insights

See more
  • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

    IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

  • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

    IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

  • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

    IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

$CAMP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more